Eyenovia獲得了5000萬美元的私人位置，任命新的CIO，並使用Hype Sigkens潛入加密貨幣。這是生物技術的未來嗎？

Eyenovia's Bold Leap: Private Placement Fuels Crypto Treasury and New CIO

Eyenovia的Bold Leap：私人位置燃料加密貨幣和新CIO

Eyenovia is making waves with a $50 million private placement, a new Chief Investment Officer, and a foray into cryptocurrency. Let's dive into what this means for the company and its investors.

Eyenovia正在以5000萬美元的私人位置，新的首席投資官以及對加密貨幣的嘗試。讓我們深入了解這對公司及其投資者意味著什麼。

Eyenovia Secures $50 Million Private Placement

Eyenovia獲得了5000萬美元的私人安置

On June 17, 2025, Eyenovia announced the closing of a $50 million private placement with institutional investors. This substantial funding is earmarked for building a treasury reserve of HYPE tokens, the native currency of the Hyperliquid blockchain. It is strategic move, positioning Eyenovia at the intersection of biotech and digital finance.

2025年6月17日，Eyenovia宣布關閉了與機構投資者的5000萬美元私人安置。這筆可觀的資金專門用於建立高流利區塊鏈的原始貨幣的炒作代幣儲備。這是戰略性的舉動，將Eyenovia定位在生物技術和數字融資的交匯處。

New CIO and Crypto Strategy

新的CIO和加密策略

Hyunsu Jung has been appointed as Chief Investment Officer and Board Member, signaling Eyenovia's serious commitment to its new cryptocurrency treasury strategy. According to Eyenovia, this initiative aims to unlock long-term value for shareholders by capitalizing on the growing adoption of digital currencies. Jung stated that the purchase of HYPE tokens paves the way for deeper engagement in the Hyperliquid ecosystem.

Hyunsu Jung被任命為首席投資官兼董事會成員，這表明Eyenovia對其新的加密貨幣國庫策略的認真承諾。根據Eyenovia的說法，該計劃旨在通過利用日益增長的數字貨幣來利用股東的長期價值。榮格說，購買炒作令牌為更深入的生態系統鋪平了道路。

Optejet Development on Track

optejet開發在正軌上

While venturing into the crypto world, Eyenovia remains focused on its core business: ophthalmic technology. The development of the Gen-2 Optejet User Filled Device (UFD) is progressing as planned, with FDA registration targeted for September 2025. Eyenovia is also exploring partnerships for the device, initially focusing on applications like OTC lens rewetting and artificial tears. The Optejet UFD could make eye treatments easier and safer, helping people stick to their care routines.

在進入加密貨幣世界時，Eyenovia仍然專注於其核心業務：眼科技術。 Gen-2 OpteJet用戶填充設備（UFD）的開發正在按計劃進行，FDA註冊針對2025年9月。 Eyenovia還在探索該設備的合作夥伴關係，最初著重於OTC Lens Rens Rens Rewetting和人工眼淚等應用。 OpteJet UFD可以使眼睛治療更加輕鬆，更安全，從而幫助人們堅持他們的護理程序。

Eyenovia Eyes Rebrand as HYPE Investment Strategy Expands

Eyenovia Eyes Rebrand隨著炒作投資策略的擴展

Pending Board approval, Eyenovia is expected to change its name and ticker to “Hyperion DeFi” and “HYPD,” respectively, reflecting its new focus on both eye care and digital finance. This rebranding underscores the company's vision of blending eye care innovation with Web3.

董事會批准，Eyenovia有望將其名稱和股票更改為“ Hyperion Defi”和“ Hypd”，這反映了其對眼部護理和數字融資的新關注。這種重塑強調了該公司將眼保健創新與Web3融合的願景。

The Downside?

缺點？

Not everyone is bullish on Eyenovia's prospects. TipRanks’ AI Analyst, Spark, rates EYEN as an Underperform, citing poor financial performance, significant operational losses, and a weak balance sheet. Spark’s analysis notes that while there is revenue growth, the negative equity and insufficient cash flow generation are critical risks. Technical indicators also point to a bearish trend, and the valuation metrics are unappealing due to a negative P/E ratio and absence of dividends.

並非每個人都看好Eyenovia的前景。 Tipranks的AI分析師Spark，將Eyen評為表現不佳，理由是財務績效不佳，運營損失巨大和資產負債表薄弱。 Spark的分析指出，儘管收入增長，但負股權和現金流量不足是關鍵風險。技術指標還指出了看跌趨勢，由於市盈率負和股息的缺乏，估值指標卻沒有吸引力。

Final Thoughts

最後的想法

Eyenovia's bold move into cryptocurrency is certainly a conversation starter. While the company faces financial headwinds, its innovative spirit and strategic shift could pave the way for future growth. Whether it's a stroke of genius or a risky gamble remains to be seen, but one thing's for sure: Eyenovia is not afraid to shake things up. Will they make it rain HYPE? Only time will tell!

Eyenovia大膽進入加密貨幣的行動無疑是對話的開始。儘管該公司面臨財務逆風，但其創新精神和戰略轉變可能為未來的增長鋪平道路。無論是天才還是冒險的賭博，還有待觀察，但可以肯定的是：Eyenovia不怕搖動一切。他們會讓下雨炒作嗎？只有時間會證明！